Professor of Medicine and Epidemiology
Principal Investigator, AIDS Clinical Research Group
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Committees and Organizations
- Member, IAS–USA Antiretroviral Guidelines Committee (2007-present)
- Elizabeth Glaser Award Advisory Board, Pediatric AIDS Foundation
Honors and Awards
- Edward Weisband Distinguished Alumnus Award for Public Service, SUNY Binghamton (2005)
- Lifetime Member, International Association of Physicians in AIDS Care (IAPAC) (2005)
- UNC-CH Distinguished Teaching Award for Post-Baccalaureate Instruction (2005)
- Alpha Omega Alpha, Medical Honor Society (nominated by UNC Medical Students) (2000)
- UNC-CH Junior Faculty Development Award (1995)
- Medicine Housestaff Teaching Award at University of North Carolina, Chapel Hill (1994)
- State University of New York at Binghamton, BS Biochemistry (1980)
- Harvard Medical School, MD (1984)
- Massachusetts General Hospital, Residency, Internal Medicine (1984–1987)
- Massachusetts General Hospital, Fellowship, Infectious Diseases (1989–1992)
- Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
- Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ Jr, Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol. 2010;171:198-205.
- Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis. 2010;201:293-296.
- Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7. pii: e1000321.
- Eron JJ Jr, Park JG, Haubrich R, et al. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009;53(6):2335-2341.
- Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.